59 60
Introduction
Dermatan sulfate (DS) is a linear polysaccharide that is covalently attached to specific core proteins forming DS-proteoglycans (DS-PGs), which are widely expressed at cell surfaces and extracellular matrices [1] . DS is abundantly distributed in the skin, cartilage, and aorta, and consists of alternating disaccharide units of L-iduronic acid (IdoUA) and N-acetyl-D-galactosamine (GalNAc) with 50-200 repeats [2] . DS chains are irregularly modified by sulfation at the hydroxy groups of C-2 on IdoUA and the C-4 positions of GalNAc residues, respectively, and are involved in the regulation of a number of biological functions such as the assembly of extracellular matrices, signal transduction, wound healing, and anticoagulation through interactions with growth factors [3, 4] .
The biosynthesis of repeating disaccharide regions of DS chains is initiated by the formation of chondroitin as a precursor backbone, which is composed of alternating Dglucuronic acid (GlcUA) and GalNAc. Chondroitin is synthesized on the carbohydrateprotein linkage region tetrasaccharide sequence (GlcUA-galactose-galactose-xylose) attached to the Ser residues of specific core proteins by various glycosyltransferases. DS-epimerase (DSE) then converts GlcUA into IdoUA by epimerizing the C-5 position of GlcUA residues after the formation of the chondroitin backbone [5] . Dermatan chains are subsequently matured by sulfation reactions catalyzed by dermatan 4-O-sulfotransferase-1 (D4ST1), also named carbohydrate sulfotransferase 14 (CHST14), and uronosyl 2-O-sulfotransferase, which transfer a sulfate group from the sulfate donor 3'-phosphoadenosine 5'-phosphosulfate to the C-4 position of GalNAc and C-2 position of IdoUA residues, respectively [6-8].
Ehlers-Danlos syndrome (EDS) is a heterogenous group of heritable connective tissue disorders characterized by skin hyperextensibility, joint hypermobility, and tissue fragility, and has been classified into six major types: the classical type (MIM#130000), hypermobility type (MIM#130020), vascular type (MIM#130050), kyphoscoliosis type (MIM#225400), arthrochalasia type (MIM#130060), and dermatospraxis type (MIM#225410) [9, 10] . The   121  122  123  124  125  126  127  128  129  130  131  132  133  134  135  136  137  138  139  140  141  142  143  144  145  146  147  148  149  150  151  152  153  154  155  156  157  158  159  160  161  162  163  164  165  166  167  168  169  170  171  172  173  174  175  176  177  178  179  180 dominant negative effects of a haploinsufficiency in mutant procollagen -chain genes or deficiency in collagen-processing enzymes have been identified as the basis for these types of EDS [9] . Additional forms of EDS have also been identified in association with molecular and biochemical abnormalities [10, 11] . EDS caused by biallelic mutations in CHST14 was recently identified in three independently reported conditions: a rare type of arthrogryposis syndrome, "adducted thumb-clubfoot syndrome" [12] , a specific type of EDS, "EDS, Kosho
Type" [13, 14] , and a subset of kyphoscoliosis-type EDS without a lysyl hydroxylase deficiency, "musculocontractural EDS" [15] . All these conditions are now concluded to be a single clinical entity, with the proposed names "D4ST1-deficient EDS (DDEDS)" [16] , "EDS caused by a CHST14/D4ST1 deficiency" [11] , or "EDS, musculocontractural type 1 (EDSMC1) (MIM#601776) in order to distinguish a subsequently identified form of EDS caused by biallelic loss-of-function mutations in DSE, which is registered as "EDS, musculocontractural type 2 (EDSMC2)" (#615539) [17, 18] . To date, 40 patients from 27 families have been reported to have a CHST14/D4ST1 deficiency, manifesting multiple congenital malformations (craniofacial characteristics, multiple congenital contractures, and visceral or ophthalmological malformations) and progressive multisystem fragility-related complications (skin hyperextensibility, bruisability, and fragility with atrophic scars; recurrent dislocations; progressive talipes or spinal deformities; pneumothorax or pneumohemothorax; large subcutaneous hematomas; and diverticular perforation) [10] [11] [12] [13] [14] [15] [19] [20] [21] [22] [23] [24] [25] [26] .
Sulfotransferase activity toward dermatan in the skin fibroblasts of affected EDS patients with CHST14 mutations was previously shown to be significantly lower in a patient (p.P281L/p.Y293C) (6.7%) and in another patient (p.P281L/p.P281L) (14.5%) than in each age-and sex-matched control [14] . A disaccharide compositional analysis of chondroitin sulfate (CS)/DS chains using the affected skin fibroblasts of these two patients showed a negligible amount of DS and excess amount of CS [14] , presumably due to an impaired 4-Osulfation lock and subsequent back-epimerization from IdoUA to GlcUA because of a 181  182  183  184  185  186  187  188  189  190  191  192  193  194  195  196  197  198  199  200  201  202  203  204  205  206  207  208  209  210  211  212  213  214  215  216  217  218  219  220  221  222  223  224  225  226  227  228  229  230  231  232  233  234  235  236  237  238  239  240 5 CHST14/D4ST1 deficiency [12, 14, 18] . Decorin is a major DS-PG in the skin and plays an important role in the assembly of collagen fibrils, possibly through an electrostatic interaction between decorin glycosaminoglycan (GAG) chains and adjacent collagen fibrils [27) . CS, but not DS dissacharides have been detected in the GAG chain of decorin from affected skin fibroblasts, while DS disaccharides (approximately 95%) have mainly been found in the GAG chain of decorin from control skin fibroblasts [14, 18] . Transmission electron microscopy revealed that collagen fibrils in affected skin specimens were dispersed in the reticular dermis, in contrast to the regularly and tightly assembled collagen fibrils observed in the controls [14] .
Each collagen fibril in the affected skin specimens was smooth and round, and did not vary in size or shape, similar to that of the controls [14] . These findings indicate that skin fragility in patients with a CHST14/D4ST1 deficiency is caused by the impaired assembly of collagen fibrils through the replacement of a DS chain with a CS chain of decorin, which may alter the electrostatic binding of decorin to collagen fibrils [10, 11, 14] .
We herein present our results on the first attempt to perform a disaccharide compositional analysis on CS/DS chains in the urine samples of patients with the disorder, which demonstrate the systemic effects of a CHST14/D4ST1 deficiency and also indicate the potential of this analysis as a non-invasive screening method for this disorder.
Materials and methods

Patient materials
Urine samples were obtained from seven previously reported patients with EDS caused by a CHST14/D4ST1 deficiency [13, 19, 20, 25] , 15 healthy subjects (aged 6 months and 3−43 years old; 10 females, 5 males), and the parents (42 and 37 years old) and unaffected sisters (3 and 11 years old) of patients #D7 and D8 (Table 1) . 
Materials
Quantification of urinary DS
The disaccharide compositions of the CS and DS chains in urine samples were assessed as described previously [28] . Briefly, urine samples were concentrated and desalted using Amicon Ultra-0.5 (10 k) centrifugal filter units (Millipore, Billerica, MA). After an aliquot was individually digested with chondroitinase ABC, a mixture of chondroitinase AC-I and AC-II, or chondroitinase B, each digest was labeled with 2AB, and excess 2AB reagents were removed by extraction with chloroform. The 2AB-labeled digest was analyzed by anionexchange HPLC on a PA-G silica column (4.6 x 150 mm, YMC Co., Kyoto, Japan) using isocratic conditions with 16 mM of NaH 2 PO 4 for the first 10 min followed by a linear gradient from 16 to 530 mM NaH 2 PO 4 at room temperature over a 60-min period at a flow rate of 0.5 ml/min. The eluates were monitored using a fluorometric detector with excitation and emission wavelengths of 330 and 420 nm, respectively. The identification and quantification of the resulting disaccharides were achieved by comparisons with the elution positions of CS-or DS-derived authentic unsaturated disaccharides. The amounts of CS and DS were normalized by urine creatinine levels, which were measured using the kit, LabAssay™ Creatinine (Wako, Osaka, Japan). This study was approved by the local Ethics Committees of Meijo University (Nagoya, Japan), Hokkaido University (Sapporo, Japan), and Shinshu University (Matsumoto, Japan). 301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335  336  337  338  339  340  341  342  343  344  345  346  347  348  349  350  351  352  353  354  355  356  357  358  359  360 
Results
The 4-O-sulfated disaccharide unit, ∆HexUA-GalNAc(4-O-sulfate), in which ∆HexUA stands for 4,5-unsaturated hexuronic acid, in CS/DS was predominantly detected in the urine samples of healthy controls and EDS patients ( Fig. 1 and Table 2 ). The non-sulfated and 6-Osulfated disaccharide units, ∆HexUA-GalNAc and ∆HexUA-GalNAc(6-O-sulfate), respectively, were also detected (Table 2) . Furthermore, a small proportion of disulfated disaccharide units including ∆HexUA(2-O-sulfate)-GalNAc(4-O-sulfate), ∆HexUA(2-Osulfate)-GalNAc(6-O-sulfate), and ∆HexUA-GalNAc(4-O-, 6-O-sulfate ) was found ( Table 2 ).
The total amount of CS/DS in urine is known to vary depending on sex and age [29] . An average value for the total amount of CS/DS disaccharides from healthy subjects (#N6 and N7), who were approximately 30-and 20-year-old males, respectively, was 7.5 nmol/mg creatinine ( Table 2 ). In contrast, an average value of 14.0 nmol/mg creatinine was detected in the urine of healthy subjects #N3 and N4 (29-year-old females). The average of total CS/DS disaccharides from 3-year-old female controls (#N9 and N10) was 72.2 nmol/mg creatinine (Table 2) . Thus, in order to compare urinary CS and DS between a healthy control and patient, sex-and age-matched controls are required.
The amount of CS/DS (6.2 nmol/mg creatinine) was markedly lower in the urine sample of patient #D2 than in those of control samples #N3 and N4 (16.4 and 9.6 nmol /mg creatinine, respectively) based on the results of chondroitinase ABC digestion (Table 2 and (Table 2 and Fig. 2) . However, the amount of CS/DS in urine samples from patient #D3 was slightly higher than that of the corresponding control (Fig. 2) .
The amount of CS disaccharides generated by digestion with chondroitinase AC (Table 3 and Fig. 2B ) was similar to that of CS/DS disaccharides obtained by digestion with chondroitinase ABC (Table 2 and Fig. 2A ). The concentration of CS disaccharides in the urine of patient #D2 (p.P281L/p.P281L) was 5.6 nmol/mg creatinine (Table 3). On the other   361  362  363  364  365  366  367  368  369  370  371  372  373  374  375  376  377  378  379  380  381  382  383  384  385  386  387  388  389  390  391  392  393  394  395  396  397  398  399  400  401  402  403  404  405  406  407  408  409  410  411  412  413  414  415  416  417  418  419  420 8 hand, those of the corresponding healthy controls, #N3 and N4, were 18.1 and 8.8 nmol/mg creatinine, respectively (Table 3) . Thus, the amount of CS in urine samples was slightly lower in the patient than in the healthy controls.
DS disaccharide was not detected in the urine of any patient, but was present in the urine of healthy controls (0.2~1.2 nmol/mg creatinine) ( Table 4 ).
The amounts of urinary CS and DS in family members of EDS patients #D7 and #D8 were also measured (Supplemental Table S1 ). The amounts of CS disaccharides from the father (P281L/+) and mother (F209S/+) of patients #D7 and D8 (F209S/P281L) were 3.3 and 7.0 nmol/mg creatinine, respectively (Supplemental Table S1 ). The amounts of urinary CS from the sisters, who have no phenotypes with EDS, of the patients were 22.8 and 47.8 nmol/mg creatinine, respectively (Supplemental Table S1 ). On the other hand, the amounts of DS disaccharides were 0.2 ~ 1.6 nmol/mg creatinine in the father, mother, and sisters of patients #D7 and D8 (Supplemental Table S1 ). The amounts of CS and DS from family members of patients were similar to those from respective sex-matched and closely agematched normal subjects (Tables 3 and 4) . Heterozygous carriers for CHST14 mutations, with no phenotypic features of the disorder, showed a similar level of DS to healthy subjects with no genotypic information available.
Discussion
In the present study in which a disaccharide compositional analysis was performed on urinary CS and DS chains in patients with EDS caused by a CHST14/D4ST1 deficiency, DS chains were not detected in any patient, which was significantly different from age-and sexmatched healthy controls. These results suggest general DS depletion in this disorder; previous findings only showed DS depletion in skin fibroblasts, and not in urine [12, 14, 18, 24] . These results also indicate the usefulness of a urinary disaccharide compositionnal analysis of CS/DS chains as a non-invasive screening method for this disorder. 423  424  425  426  427  428  429  430  431  432  433  434  435  436  437  438  439  440  441  442  443  444  445  446  447  448  449  450  451  452  453  454  455  456  457  458  459  460  461  462  463  464  465  466  467  468  469  470  471  472  473  474  475  476  477  478  479  480 In the cultured skin fibroblasts of patients with EDS caused by a CHST14/D4ST1 deficiency, the DS side chain on DS-PG, decorin, was found to be replaced by CS, resulting in the disruption of the assembly of collagen fibrils [14, 18] . The loss of decorin in mice was previously reported to cause abnormal collagen fibrogenesis and skin fragility [30] , and affected the binding of fibroblast growth factor-7 (FGF7) and FGF2 to keratinocytes [31] .
Thus, post-translational modifications induced in decorin by DS play an important role in collagen fibril assembly and FGF signaling. Several frameshift mutations in the decorin gene 481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540 susceptibility to atrophic scarring of the skin [17] . The enzymatic activity of DSE in fibroblasts from these patients was significantly weaker than that of healthy subjects [17] . In addition, the amount of DS from the fibroblasts of these patients was less than that in the control [17] . It may be difficult at present, with no urinary DS data available on patients with DSE deficiency, to identify which of the genes, CHST14 or DSE, are associated with DSdefective EDS by measuring urinary DS.
The major characteristics of the kyphoscoliosis type of EDS are severe muscle hypotonia, generalized joint laxity, and scoliosis [37] . This type of EDS is caused by mutations in PLOD1 encoding lysyl hydroxylase 1 (procollagen-lysine 2-oxoglutarate 5-dioxygenase 1), which hydroxylates lysyl residues on procollagen -chains. The ratio of urinary lysyl pyridinoline to hydroxylysyl pyridinoline in these patients is abnormally high [38] . D4ST1-defective EDS has been classified as the kyphoscoliosis type of EDS without a lysyl hydroxylase deficiency (EDS-type VIB), based on similarities to the characteristic facial and skeletal features of the kyphoscoliosis type of EDS (EDS-type VIA) [13, 19] . Thus, the quantification of urinary DS is also a useful diagnostic test for identifing the kyphoscoliosis type of EDS with lysyl hydroxylase or D4ST1 deficiencies.
Chst14/D4st1-deficient mice have smaller body weights, kinked tails, and more fragile skin and are also less fertile than the wild type [39] . In addition, the impaired proliferation of neural stem cells, reduced neurogenesis, and altered subpopulations of radial glial cells have been demonstrated in Chst14/D4st1-deficient mice [40] . These phenotypes are partially consistent with those of patients with EDS caused by a CHST14/D4ST1 deficiency. However, the amount of the DS chain in Chst14 -/-/D4st1 -/-mice was not reported in detail. An analysis of urinary DS in the knockout mice may support our results.
Conclusion
In conclusion, this is the first study to perform a urinary disaccharide compositional 541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587  588  589  590  591  592  593  594  595  596  597  598  599  600 analysis on CS/DS chains in patients with EDS caused by a CHST14/D4ST1 deficiency, and demonstrate the absence of DS chains. This result suggests systemic DS depletion in this disorder, and also proposes the usefulness of a urinary disaccharide compositional analysis of CS/DS chains as a non-invasive screening method for this disorder.
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CHST14, carbohydrate sulfotransferase 14; C4ST, chondroitin 4-O-sulfotransferase; CS,
Urine samples were individually digested with a mixture of chondroitinases AC-I and AC-II for the analysis of CS only, and each digest was treated with 2-AB to label the yielded CS-derived disaccharides, which were analyzed by anion-exchange HPLC (Fig. 1) 
